Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines

OBJECTIVES: Patients with highly resistant tuberculosis have few treatment options. Bedaquiline, pretomanid and linezolid regimen (BPaL) is a new regimen shown to have favourable outcomes after six months. We present an economic evaluation of introducing BPaL against the extensively drug-resistant t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomez, Gabriela Beatriz, Siapka, Mariana, Conradie, Francesca, Ndjeka, Norbert, Garfin, Anna Marie Celina, Lomtadze, Nino, Avaliani, Zaza, Kiria, Nana, Malhotra, Shelly, Cook-Scalise, Sarah, Juneja, Sandeep, Everitt, Daniel, Spigelman, Melvin, Vassall, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647530/
https://www.ncbi.nlm.nih.gov/pubmed/34862287
http://dx.doi.org/10.1136/bmjopen-2021-051521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647530/
https://www.ncbi.nlm.nih.gov/pubmed/34862287
http://dx.doi.org/10.1136/bmjopen-2021-051521

Ejemplares similares